Идёт набор NCT07219238

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Фаза II / Фаза III С лечением Colorectal Cancer Gastric Cancers Ovarian Cancers Pancreatic Ductal Adenocarcinoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT).
Кому может быть актуально: Состояния в реестре: Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Швеция
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Обзор

This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study. The study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET/CT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET/CT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.

Вмешательства

Препарат GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
Attenuation correction CT will commence after the administration of GEH300079 (68Ga), and immediately before the PET acquisition. The PET acquisition will encompass the participant's vertex through mid-thighs. Images will be acquired at 60 ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

Первичные конечные точки

Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC. [Срок оценки: Single time point. Images will be acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]

Вторичные конечные точки (12)

Superiority of the per region sensitivity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging and non-inferiority of the per region specificity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging. [Срок оценки: Single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
Superiority of the per participant sensitivity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging in Phase 3 [Срок оценки: Single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
Per region PPV, NPV, and accuracy and per participant sensitivity, specificity PPV, NPV, and accuracy of GEH300079 (68Ga) PET/CT and baseline SoC imaging to detect PC [Срок оценки: Single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
Correlation between radiological and surgical/laparoscopic PCI scores [Срок оценки: Single time point. Baseline SoC images. GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes. Surgery/laparoscopy within 28 days post injection]
The number of Positive peritoneal regions and percentage of participants with a difference in the number of Positive peritoneal regions. [Срок оценки: single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
SUVmax of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT. [Срок оценки: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
SUVmean of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT. [Срок оценки: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
SUVpeak of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT. [Срок оценки: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
Tumor to-background ratio (TBR) of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT. [Срок оценки: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
Contrast-to-noise ratio (CNR) of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT. [Срок оценки: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.]
Correlation between FAP expression and GEH300079 (68Ga) PET/CT uptake in PC from different primary cancer in Phase 2 [Срок оценки: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes. Surgery/laparoscopy within 28 days post injection]
Percentage of participants for whom GEH300079 (68Ga) PET/CT could have led to a change in treatment plan [Срок оценки: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection]

Критерии участия

Критерии включения

Participant is ≥18 years of age
Participant has provided signed informed consent before any study-specific screening procedures
Participant has histopathologically confirmed primary colorectal, gastric or ovarian cancer or PDAC
Participant has known or suspected PC from the tumor of origin. Suspicion may be based on imaging or clinical findings.
Participant is scheduled for peritoneal surgery with curative intent, surgical exploration, or laparoscopy, with either: a. No neoadjuvant treatment received, treatment-naïve (i.e., undergoing upfront surgery or laparoscopy) b. Completed systemic treatment (which may include neoadjuvant chemotherapy) before GEH300079 ( 68Ga) PET/CT Imaging Visit
Participant has Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Participant is able and willing to comply with all study procedures as described in the protocol

Критерии исключения

Participant is pregnant or breast-feeding, or sexually active and not using or not willing to use an acceptable form of birth control from screening up to 30 days after receiving the investigational medicinal product (IMP)
Participant has a known disorder that, in the opinion of the investigator, will impact the study procedures
Participant needs any intervention that would delay study participation
Participant has non-resectable extra-abdominal metastasis and/or >3 hepatic metastases on standard work up
Participant will not be able to complete the study, based on their anticipated life expectancy
Participant has active bacterial, viral, or fungal infection requiring systemic antibacterial, anti-viral or antifungal therapy (topical medications are permitted)
Participant has renal function impairment as defined by:

For Phase 2: estimated glomerular filtration rate less than 60 mL/min
For Phase 3: estimated glomerular filtration rate less than 30 mL/min
Participant has severe hepatic function impairment as defined by:

Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase) and alanine aminotransferase (serum glutamic-pyruvic transaminase): ≤2.5 × upper limit of normal (ULN; ≤5 × ULN for participants with liver metastases)
Bilirubin: ≤1.5 × ULN or direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN
Participant has autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed
Participant has serious co-morbidities or serious non-malignant disease that in the opinion of the investigator, could compromise participant safety and/or protocol objectives
Participant either received or is planning to receive any other investigational agent within the 28 days prior to the first imaging visit or during study participation (with the exception of the 3-month follow-up period)
Participant has known or suspected hypersensitivity to any excipients used in GEH300079 (68Ga)
Participant has severe claustrophobia, is unable to lie flat or fit into the scanner, or is unable to tolerate the PET/CT scan for any reason
(Phase 3 only) Participant was previously included in Phase 2 of this study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет